logo
Plus   Neg
Share
Email

ViiV Healthcare: GEMINI 1&2 Studies Meets Primary Endpoint - Quick Facts

ViiV Healthcare reported positive headline results from its phase III GEMINI study programme. The studies (GEMINI-1 and GEMINI-2) are designed to evaluate the safety and efficacy of a two-drug regimen of dolutegravir and lamivudine compared to a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors, tenofovir disoproxil fumarate/emtricitabine, in treatment naïve HIV-1 infected adults with baseline viral loads less than 500,000 copies per ml. The company said the studies met their primary endpoint for non-inferiority based on plasma HIV-1 RNA <50 copies per millilitre, a standard measure of HIV control, at Week 48.

The company said the safety results for the 2DR of dolutegravir and lamivudine were consistent with the product labelling for the medicines. No patient who experienced virologic failure in either treatment arm developed treatment-emergent resistance.

Full results from the studies will be presented at an upcoming scientific meeting. ViiV will now plan for regulatory submissions for the two-drug regimen of dolutegravir and lamivudine later in the current year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Even as luxury electric car maker Tesla Inc. may go private, Chinese rival Nio is seeking to raise $1.8 billion in an initial public offering on the New York Stock Exchange. The electric vehicle start-up is the first Chinese automaker to file for a U.S. listing. It plans to list its shares on the New York Stock Exchange under the symbol 'NIO.' Luxury electric car maker Tesla, Inc. said Tuesday that its board of directors has formed a special committee to evaluate CEO Elon Musk's previously announced consideration of a transaction to take the company private. Tesla said that the special committee, comprised of three independent directors, has not yet received a formal proposal from Musk regarding any going private transaction. The Home Depot (HD) reported second-quarter net earnings of $3.5 billion, or $3.05 per share, compared to $2.7 billion, or $2.25 per share, last year. For the second quarter, earnings per share increased 35.6% from the same period in the prior year. On average, 30 analysts polled by Thomson Reuters expected...
Follow RTT